Clinical Trial

Clinical Study of Compound Ciwujia Granules in the Treatment of Depression

Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated April 23, 2026 (before its estimated June 20, 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this clinical trial is to evaluate the therapeutic efficacy and safety of Compound Ciwujia Granules in treating depression disorder (heart-spleen deficiency syndrome). The study primarily aims to address the following key questions: * Can Compound Ciwujia Granules effectively alleviate depressive symptoms in patients with heart-spleen deficiency syndrome? * What adverse reactions might participants experience while taking Compound Ciwujia Granules? Researchers will compare Compound Ciwujia Granules to a placebo (a look-alike substance that contains no drug) to see if Compound Ciwujia Granules works to treat depression disorder. Participants are required to complete the following procedures: 1. Take Compound Ciwujia Granules or placebo twice daily for 8 weeks; 2. Continue concomitant SSRIs throughout the treatment period; 3. Return to the hospital for scheduled assessments at Week 4 and Week 8.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-07-17; most recent amendment 2026-04-20.
Status change: Not Yet Recruiting → Active, Not Recruiting 2026-04-20
Trial Details
NCT Number NCT07085143
Lead Sponsor Shanghai Mental Health Center
Collaborators: Heilongjiang Quanle Pharmaceutical Co., Ltd.
Conditions Depression - Major Depressive Disorder, Depression Disorders
Enrollment 60 participants
Start Date 2025-10-01
Primary Completion 2026-06-20 (estimated)
Study Completion 2026-07-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-23